Alexion Pharmaceuticals has acquired Massachusetts-based biotechnology firm, Taligen Therapeutics, Reuters reports. The Connecticut-based pharmaceutical company paid $111 million for the acquisition.
Taligen’s staff will form the nucleus of Alexion’s new Translational Medicine Group, which will be headed by Abbie Celniker, former CEO of Taligen, adds Republican American. Alexion will also provide 2011 financial guidance in February, including one-time expenses related to the deal.
Click here for the story from Reuters.
Click here for additional coverage from Republican American.